PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-Free HIV Therapeutic DNA Vaccine

PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine

GOLDEN, Colo.--(BUSINESS WIRE)--Jun 19, 2025-

PharmaJet and Immuno Cure partner to advance needle-free HIV therapeutic DNA vaccine - BioTuesdays

Closely held PharmaJet announced that it has signed an agreement with closely held Immuno Cure, a developer of DNA vaccines. Under the agreement, Immuno Cure will use PharmaJet’s Tropis Intradermal (ID) Needle-Free Injection System in a human clinical trial to deliver its novel HIV-1 therapeutic DNA vaccine, ICVAX. The agreement was formalized on June 16, 2025, during a signing ceremony at the 2025 BIO International Convention in Boston, Massach…

Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans

HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic…